Antonella Capozzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonella Capozzi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Maurizio Sorice
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
5 shared publications - Tina Garofalo
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
4 shared publications - Roberta Misasi
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
3 shared publications - Agostina Longo
Department of Wellbeing, Health and Environmental Sustainability, Sapienza University of Rome, 00161, Rome, Italy
2 shared publications - Brigitta Buttari
Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Italian National Institute of Health, 00161 Rome, Italy
2 shared publications - Cristiano Alessandri
Lupus Clinic, Reumatologia, Dipartimento di Scienze Cliniche, Anestesiologiche Internistiche e Cardiovascolari, Sapienza Università di Roma, Rome, Italy
2 shared publications
Latest Publications
- 5 September 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1528
Recent advancements in NRF2-regulated ferroptosis modulation for targeted cancer therapy
- 5 September 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1528
Recent advancements in NRF2-regulated ferroptosis modulation for targeted cancer therapy
- Open Access
- 13 July 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (8) , 168365
Neuroglobin reduces stress-induced oxidative damage and amyloid burden in a three-dimensional human neuroblastoma cell culture
- 13 July 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (8) , 168365
Open AccessNeuroglobin reduces stress-induced oxidative damage and amyloid burden in a three-dimensional human neuroblastoma cell culture
- Open Access
- 25 September 2024
- Published by PAGEPress Publications in Reumatismo
- Vol. 76 (4)
Cryptogenic stroke and seronegative antiphospholipid syndrome: a case series of patients with positivity for “non-criteria” antiphospholipid antibodies
Cerebrovascular events (CE) are one of the most common and severe events in antiphospholipid syndrome (APS), a condition characterized by thrombosis and circulating anti-phospholipid antibodies (aPL). Seronegative APS (SN-APS) refers to a group of patients with clinical features of APS but persistently negative tests for “criteria aPL”: anti-cardiolipin antibodies (aCL) and anti-β2glycoprotein I antibodies detected by enzyme-linked immunosorbent assay (ELISA), and the lupus anticoagulant detected by clotting assays. We report a series of five cases of SN-APS in young or middle-aged patients who tested positive for “non-criteria” aPL. We retrospectively collected cases of SN-APS patients who experienced CE without an identified cause despite an extensive diagnostic work-up and tested negative for criteria aPL. All the patient sera were tested for aCL by immunostaining on thin-layer chromatography (TLC) and anti-vimentin/cardiolipin (aCL/Vim) by ELISA. We identified five cases of female patients aged 21 to 58 years, evaluated at the Rheumatology Unit and/ or Stroke Unit/Emergency Department of the Sapienza University Hospital of Rome, “Policlinico Umberto I”. All patients presented a clinical history suggestive of APS. All the patients tested positive for aCL by TLC-immunostaining, and one patient was positive for aCL/Vim. In young or middle-aged patients with cryptogenic CE and a clinical history suggestive of APS, the use of new diagnostic tools for identifying aPL, if validated in future studies, could represent an important step in the prompt diagnosis of APS.
- 25 September 2024
- Published by PAGEPress Publications in Reumatismo
- Vol. 76 (4)
Open AccessCryptogenic stroke and seronegative antiphospholipid syndrome: a case series of patients with positivity for “non-criteria” antiphospholipid antibodies
Cerebrovascular events (CE) are one of the most common and severe events in antiphospholipid syndrome (APS), a condition characterized by thrombosis and circulating anti-phospholipid antibodies (aPL). Seronegative APS (SN-APS) refers to a group of patients with clinical features of APS but persistently negative tests for “criteria aPL”: anti-cardiolipin antibodies (aCL) and anti-β2glycoprotein I antibodies detected by enzyme-linked immunosorbent assay (ELISA), and the lupus anticoagulant detected by clotting assays. We report a series of five cases of SN-APS in young or middle-aged patients who tested positive for “non-criteria” aPL. We retrospectively collected cases of SN-APS patients who experienced CE without an identified cause despite an extensive diagnostic work-up and tested negative for criteria aPL. All the patient sera were tested for aCL by immunostaining on thin-layer chromatography (TLC) and anti-vimentin/cardiolipin (aCL/Vim) by ELISA. We identified five cases of female patients aged 21 to 58 years, evaluated at the Rheumatology Unit and/ or Stroke Unit/Emergency Department of the Sapienza University Hospital of Rome, “Policlinico Umberto I”. All patients presented a clinical history suggestive of APS. All the patients tested positive for aCL by TLC-immunostaining, and one patient was positive for aCL/Vim. In young or middle-aged patients with cryptogenic CE and a clinical history suggestive of APS, the use of new diagnostic tools for identifying aPL, if validated in future studies, could represent an important step in the prompt diagnosis of APS.
- 26 December 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (1) , 261-262
Effect of heparanase inhibitor on tissue factor overexpression in platelets and endothelial cells induced by anti‐β2‐GPI antibodies: Reply to comment from Mackman et al.
- 26 December 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (1) , 261-262
Effect of heparanase inhibitor on tissue factor overexpression in platelets and endothelial cells induced by anti‐β2‐GPI antibodies: Reply to comment from Mackman et al.
- Open Access
- 1 January 2018
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2018 (1) , 2373167
Oxidative Stress Induces HSP90 Upregulation on the Surface of Primary Human Endothelial Cells: Role of the Antioxidant 7,8‐Dihydroxy‐4‐methylcoumarin in Preventing HSP90 Exposure to the Immune System
We have previously demonstrated that human heat shock protein 90 (HSP90), an intracellular self protein, is the target of cellular and humoral autoimmune responses in patients with carotid atherosclerosis. In this study, we evaluated in vitro whether oxidative stress, a feature of atherosclerotic plaque, alters HSP90 expression in endothelial cells, thus inducing surface localization of this molecule and whether the antioxidant compound 7,8‐dihydroxy‐4‐methylcoumarin (7,8‐DHMC) is able to prevent oxidative stress‐induced alterations of HSP90 localization. By the use of flow cytometry, immunofluorescence, enzyme‐linked immunosorbent assay, and semiquantitative reverse‐transcription polymerase chain reaction, we demonstrated that exposure of human umbilical vein endothelial cells (HUVEC) to the prooxidant compound H2O2 upregulated HSP90 surface expression and reduced its secretion without altering HSP90 gene expression and intracytoplasmic protein levels. Pretreatment of HUVEC with 7,8‐DHMC prevented H2O2‐induced alterations of HSP90 cellular distribution and secretion. Our results suggest that the strong oxidative conditions of atherosclerotic plaques promote the upregulation of HSP90 surface expression on endothelial cells, thus rendering the protein a possible target of autoimmune reactions. The antioxidant 7,8‐DHMC, by preventing oxidative‐stress‐triggered HSP90 surface upregulation, may be useful to counteract possible autoreactive reactions to HSP90.
- 1 January 2018
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2018 (1) , 2373167
Open AccessOxidative Stress Induces HSP90 Upregulation on the Surface of Primary Human Endothelial Cells: Role of the Antioxidant 7,8‐Dihydroxy‐4‐methylcoumarin in Preventing HSP90 Exposure to the Immune System
We have previously demonstrated that human heat shock protein 90 (HSP90), an intracellular self protein, is the target of cellular and humoral autoimmune responses in patients with carotid atherosclerosis. In this study, we evaluated in vitro whether oxidative stress, a feature of atherosclerotic plaque, alters HSP90 expression in endothelial cells, thus inducing surface localization of this molecule and whether the antioxidant compound 7,8‐dihydroxy‐4‐methylcoumarin (7,8‐DHMC) is able to prevent oxidative stress‐induced alterations of HSP90 localization. By the use of flow cytometry, immunofluorescence, enzyme‐linked immunosorbent assay, and semiquantitative reverse‐transcription polymerase chain reaction, we demonstrated that exposure of human umbilical vein endothelial cells (HUVEC) to the prooxidant compound H2O2 upregulated HSP90 surface expression and reduced its secretion without altering HSP90 gene expression and intracytoplasmic protein levels. Pretreatment of HUVEC with 7,8‐DHMC prevented H2O2‐induced alterations of HSP90 cellular distribution and secretion. Our results suggest that the strong oxidative conditions of atherosclerotic plaques promote the upregulation of HSP90 surface expression on endothelial cells, thus rendering the protein a possible target of autoimmune reactions. The antioxidant 7,8‐DHMC, by preventing oxidative‐stress‐triggered HSP90 surface upregulation, may be useful to counteract possible autoreactive reactions to HSP90.
- Open Access
- 19 December 2017
- Published by Wiley in Journal of Immunology Research
- Vol. 2017, 1-7
Elevated Serum Level of HMGB1 in Patients with the Antiphospholipid Syndrome
Pregnancy problems are common in patients with rheumatic disease; indeed, autoimmune disorders and autoantibodies can affect pregnancy progress and lead to maternal complications. Recent studies have highlighted a close association between HMGB1, chronic inflammation, and autoimmune diseases. Thus, in this investigation, we analyzed serum levels of HMGB1, an alarmin which plays a pivotal role in inducing and enhancing immune cell function. Sera from 30 patients with antiphospholipid syndrome (11 primary and 19 secondary APS), 35 subjects with pregnancy morbidity, and 30 healthy women were analysed for HMGB1 and its putative receptor RAGE (sRAGE) by Western blot and for TNF-α by ELISA. Results revealed that APS patients showed significantly increased serum levels of HMGB1, sRAGE, and the proinflammatory cytokine TNF-α, as compared to healthy women. However, also, the pregnancy morbidity subjects showed significantly increased levels of HMGB1 and sRAGE as well as TNF-α compared to healthy women. Our findings suggest that in subjects with pregnancy morbidity, including obstetric APS, elevated levels of HMGB1/sRAGE may represent an alarm signal, indicating an increase of proinflammatory triggers. Further studies are needed to evaluate the role of HMGB1/sRAGE as a possible tool to evaluate the risk stratification of adverse pregnancy outcomes.
- 19 December 2017
- Published by Wiley in Journal of Immunology Research
- Vol. 2017, 1-7
Open AccessElevated Serum Level of HMGB1 in Patients with the Antiphospholipid Syndrome
Pregnancy problems are common in patients with rheumatic disease; indeed, autoimmune disorders and autoantibodies can affect pregnancy progress and lead to maternal complications. Recent studies have highlighted a close association between HMGB1, chronic inflammation, and autoimmune diseases. Thus, in this investigation, we analyzed serum levels of HMGB1, an alarmin which plays a pivotal role in inducing and enhancing immune cell function. Sera from 30 patients with antiphospholipid syndrome (11 primary and 19 secondary APS), 35 subjects with pregnancy morbidity, and 30 healthy women were analysed for HMGB1 and its putative receptor RAGE (sRAGE) by Western blot and for TNF-α by ELISA. Results revealed that APS patients showed significantly increased serum levels of HMGB1, sRAGE, and the proinflammatory cytokine TNF-α, as compared to healthy women. However, also, the pregnancy morbidity subjects showed significantly increased levels of HMGB1 and sRAGE as well as TNF-α compared to healthy women. Our findings suggest that in subjects with pregnancy morbidity, including obstetric APS, elevated levels of HMGB1/sRAGE may represent an alarm signal, indicating an increase of proinflammatory triggers. Further studies are needed to evaluate the role of HMGB1/sRAGE as a possible tool to evaluate the risk stratification of adverse pregnancy outcomes.